
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health is well-positioned for long-term success in the metabolic disease treatment market. The strong correlation between ablation length and weight loss success in patients, along with the potential for RJVA-001 to offer a one-time gene therapy solution for type 2 diabetes, present a promising outlook for the company's future. Additionally, the expected FDA approval filing for Revita by the end of the year further supports the company's potential for growth and success.
Bears say
Fractyl Health is a clinical-stage metabolic therapeutics company focused on innovative treatments for obesity and T2D. Despite their promising lead product candidate, Revita, there are several risks to consider, including the potential for failed clinical trials, dilutive capital raises, and noncompliance with exchange requirements. However, the recent introduction of the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway may benefit Revita's development and accelerate time to broad Medicare coverage. If approved, this could enhance the near-term commercial outlook and bolster the long-term value proposition of the company's one-time procedural therapy.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares